Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tu Salud (Your Health) Randomized Control Study in Patients With Diabetes Using a Mobile App.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03556605
Recruitment Status : Unknown
Verified January 2019 by LifeScan.
Recruitment status was:  Recruiting
First Posted : June 14, 2018
Last Update Posted : January 31, 2019
Sponsor:
Information provided by (Responsible Party):
LifeScan

Brief Summary:
The study seeks to demonstrate the clinical value and user acceptance of the Bluetooth enabled OneTouch Verio® Flex meter (Flex) used in combination with the OneTouch Reveal® Mobile APP to support overall diabetes care, glycemic control and patient reported outcomes in patients with diabetes in an undeserved population.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus Other: OneTouch Reveal® Mobile APP system Other: Current Blood Glucose Monitor Not Applicable

Detailed Description:

This is a parallel arm, open-label, randomized controlled, partial cross-over study. Subjects will be randomized into intervention group or control group in a 2:1 ratio. Intervention group will use the Flex blood glucose meter and OneTouch Reveal Mobile App and receive text messages every 2 weeks from the Health Care Professional for 12 weeks. The intervention group will continue under the same conditions until 24 weeks to explore durability of effects. The control group will use their own blood glucose meter without connectivity to a diabetes app for the first 12 weeks of the study. At that point, control group subjects will cross-over to the same treatment as the intervention group for an additional 12 weeks.

A target of 100 subjects will be enrolled in the Intervention arm and a target of 50 subjects will be enrolled in the Control arm. Randomization will be stratified based on type of diabetes (Type 1 or Type 2) and A1c (above or below 9.0%). Each subject will attend visits at Screening/Baseline, 12 weeks and 24 weeks after Baseline. In most cases, Screening and Baseline will occur on the same day.

Study Periods

The study will be conducted in the following periods:

Visit 1 (Screening/Baseline): All screening procedures will be performed including informed consent, demographics, medical history, a capillary blood draw for POC A1c determination and evaluation of entrance criteria. If subject A1c meets inclusion criteria and subject meets all other inclusion criteria and none of the exclusion criteria, subject will be randomized into one of two arms via randomization scheme. The time of randomization becomes Day 1.

Visit 2 (Week 12 ± 7 days): A capillary blood draw will be performed for measurement of POC A1c. The HCP will discuss diabetes management progress with all subjects: for the control group based on their own meter data; for the intervention group, the HCP will download SMBG data from Flex meters and discuss diabetes management based on OTRM APP and Flex meter information. The HCP will review and consider if the glucose range limits on the Flex meter and/or OTRM need to be updated. Intervention subjects will continue in the same group for an additional 12 weeks. Control subjects will be switched to Flex and OTRM for 12 weeks.

Visit 3 (Week 24 ± 7 days): A capillary blood draw will be performed for measurement of POC A1c. The HCP will download SMBG data from all Flex meters. Subjects will return study materials.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Tu Salud Randomized Controlled Partial Cross-over Study in Patients With Diabetes in an Underserved Population
Actual Study Start Date : July 30, 2018
Estimated Primary Completion Date : September 15, 2019
Estimated Study Completion Date : September 15, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Sugar

Arm Intervention/treatment
Intervention Arm
A target of 100 subjects will be enrolled in the Intervention arm using the OneTouch Reveal® Mobile APP system
Other: OneTouch Reveal® Mobile APP system
Improved glycemic control in people with diabetes using the OneTouch Verio® Flex Blood Glucose Monitor and the OneTouch Reveal® Mobile APP system (intervention group) compared to subjects continuing to use their own Blood Glucose Monitor without connection to mobile diabetes apps (control group).

Control Arm.
A target of 50 subjects will be enrolled in the Control intervention arm. Subjects continue to use their current Blood Glucose Monitor without connection to mobile diabetes apps.
Other: Current Blood Glucose Monitor
Subjects continue to use current Blood Glucose Monitor without connection to mobile diabetes apps.




Primary Outcome Measures :
  1. Change in A1c from baseline at 12 weeks in intervention group compared to control group. At this point, control group subjects will cross-over to the same treatment as the intervention group for an additional 12 weeks. [ Time Frame: Each subject will attend visits at Screening/Baseline, 12 weeks and 24 weeks after Baseline. ]
    The primary objective is to demonstrate improved glycemic control in people with diabetes using the OneTouch Verio® Flex Blood Glucose Monitors and the OneTouch Reveal® Mobile APP system (intervention group) compared to subjects continuing to use their own Blood Glucose Monitor without connection to mobile diabetes apps (control group).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female , at least 18 years old.
  • Has an A1c ≥7.5 at screening visit
  • It is medically appropriate in the opinion of the investigator for the Subject to attempt to achieve a level of glycemic control in line with the ADA guidelines on glycemic recommendations (<7.0% A1c, pre-prandial capillary glucose of 70-130 mg/dl and peak post-prandial glucose of <180 mg/dl)
  • Diagnosed with T2D or T1D for ≥ 3 month before screening
  • Currently performing SMBG at home for diabetes management decisions and willing to perform SMBG ≥ 1 per day if subject has T2D and is on oral antihyperglycemic (AHA) agents and/or non-insulin injectable (e.g. GLP-1) only; test ≥ 2 times per day if on basal insulin or premixed insulin; and test ≥ 3 times per day if subject has T2D and is on multiple daily injections (MDI) or subject has T1D
  • Willing to receive (and send, if necessary) text messages every 2 weeks throughout the study using a smartphone. (note: this inclusion criteria applies to all subjects regardless of whether they are subsequently randomized to control or intervention arms)
  • Is in an area that can send and receive text messages and has access to a phone signal to use the network as required
  • Willingness to notify the study staff if they become pregnant during the study
  • Able to communicate in English or Spanish, and able to understand and sign the required study documents;
  • Sign an informed consent document indicating they understand the purpose and procedures of the study

Exclusion Criteria:

  • Unlikely to be compliant with the currently prescribed diabetes regimen, in the opinion of the study staff
  • Subject is pregnant
  • Currently using OneTouch Verio® Flex at home for routine glucose testing
  • Currently using OneTouch Reveal app
  • Currently using a continuous glucose monitor (CGM) or insulin pump
  • Has unstable (rapidly progressing) retinopathy that in the opinion of the study staff may require surgical treatment (including laser photocoagulation) during the study
  • Is currently on or received treatment during the past 3 months with the following medications: Systemic corticosteroids or anti-psychotic drugs
  • Is currently psychiatrically unstable in the opinion of the study staff
  • Has known clinically significant and/or unstable medical conditions which, in the opinion of the study staff, could interfere with participation in the study, including:
  • Cardiovascular disease
  • Hematological disease
  • Hepatic disease.
  • Gastrointestinal disease
  • Endocrine/metabolic disorders
  • Neurologic disease
  • History of major surgery within 3 months
  • Has had any condition that in the opinion of the study staff that would complicate or compromise the study, or the wellbeing of the Subject

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03556605


Contacts
Layout table for location contacts
Contact: Ferderico Ceppa +1 610-384-6550 fceppa@lchps.org

Locations
Layout table for location information
United States, Pennsylvania
La Comunidad Hispana (LCH) Health Center Recruiting
West Chester, Pennsylvania, United States, 19348
Sponsors and Collaborators
LifeScan
Investigators
Layout table for investigator information
Principal Investigator: Frederico Ceppa La Comunidad Hispana Health Center
Layout table for additonal information
Responsible Party: LifeScan
ClinicalTrials.gov Identifier: NCT03556605    
Other Study ID Numbers: PR3170365
First Posted: June 14, 2018    Key Record Dates
Last Update Posted: January 31, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases